Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan G Richards

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cancer Biology & Therapy|August 28, 2010
CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapyYu-Hung Huang, Joseph A Cozzitorto, Nathan G Richards, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 11, 2012
Serum blood urea nitrogen and serum albumin on the first postoperative day predict pancreatic fistula and major complications after pancreaticoduodenectomyDaniel M Relles, Nathan G Richards, Jordan P Bloom, et al.
Expert Opinion on Drug Delivery|March 6, 2010
Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the futureShayna L Showalter, Sarah Charles, Justin Belin, et al.
Annals of Surgery|August 27, 2010
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patientsNathan G Richards, David W Rittenhouse, Boris Freydin, et al.
World Journal of Surgery|May 24, 2026
Building Surgical Capacity Through Multidisciplinary Laparoscopic Cholecystectomy Training in Kampong Cham, CambodiaLeif Manuel Sorensen, Sin Pengleap, Anna M Darelli-Anderson, et al.
Plos One|December 15, 2010
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAsTimothy K Williams, Christina L Costantino, Nikolai A Bildzukewicz, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer Biology & Therapy|August 28, 2010
CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapyYu-Hung Huang, Joseph A Cozzitorto, Nathan G Richards, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 11, 2012
Serum blood urea nitrogen and serum albumin on the first postoperative day predict pancreatic fistula and major complications after pancreaticoduodenectomyDaniel M Relles, Nathan G Richards, Jordan P Bloom, et al.
Expert Opinion on Drug Delivery|March 6, 2010
Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the futureShayna L Showalter, Sarah Charles, Justin Belin, et al.
Annals of Surgery|August 27, 2010
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patientsNathan G Richards, David W Rittenhouse, Boris Freydin, et al.
World Journal of Surgery|May 24, 2026
Building Surgical Capacity Through Multidisciplinary Laparoscopic Cholecystectomy Training in Kampong Cham, CambodiaLeif Manuel Sorensen, Sin Pengleap, Anna M Darelli-Anderson, et al.
Plos One|December 15, 2010
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAsTimothy K Williams, Christina L Costantino, Nikolai A Bildzukewicz, et al.
Pageof 2